ReviewFrontiers in immunology2026
Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) remains a leading cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HSCT). This review provides a concise overview of the clinical spectrum of GVHD, including classical acute GVHD (aGVHD), chronic GVHD (cGVHD), and overlap syndromes as defined by the NIH Consensus Criteria. We summarize key advances in precision diagnostics, including the ST2/REG3α MAGIC biomarker panel, novel B-cell subsets (cGPS), which derive from a CD27+CD86+CD20- B-cell subpopulation, and transcriptomic profiling using single-cell RNA sequencing (scRNA-seq) and plasma cell-free RNA (cfRNA). We also examine extracellular vesicles and loss of gut microbiota diversity as critical drivers of pathogenesis. Finally, we analyze the current therapeutic landscape, distinguishing between 2024 prophylaxis recommendations and newly approved treatments for steroid-refractory disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.